T
Terns Pharmaceuticals D
D
TERN
52.705
USD
0.03
(0.06%)
مغلق
حجم التداول
147,018
الربح لكل سهم
-1
العائد الربحي
-
P/E
-51
حجم السوق
6,082,862,825
الأخبار المقالات
العنوان: Terns Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs.